Market Overview

UPDATE: Credit Suisse Initiates Arena Pharmaceuticals at Underperform on Belviq Expectations

Share:
Related ARNA
Arena Pharma Could Be Developing Several Best-In-Class Agents
15 Biggest Mid-Day Gainers For Friday

Credit Suisse initiated its Arena Pharmaceuticals (NASDAQ: ARNA) at Underperform with a $6 price target.

Credit Suisse noted, "We are initiating with an Underperform rating and a $6 target price. ARNA commendably ushered Belviq through FDA; we believe that sales (ARNA has a ~35% royalty) will fall short of the market's lofty expectations."

Arena Pharmaceuticals closed at $9.16 on Wednesday.

Latest Ratings for ARNA

DateFirmActionFromTo
May 2017Leerink SwannInitiates Coverage OnOutperform
Sep 2016FBR CapitalInitiates Coverage onOutperform
Nov 2013WallachbethInitiates Coverage onBuy

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (ARNA)

View Comments and Join the Discussion!